ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Oncology and Hematology News and Journal Articles

Defining Value in Radiation Oncology: Approaches to Weighing Benefits vs Costs

Value in its essence is preference or outcome divided by cost, or described in terms of a mathematical equation, value = outcome (preference)/cost. It follows, then, that value is increased by holding outcome constant and reducing cost, or by improving outcome while holding cost constant.

Recent Content

Researchers evaluated cervical cancer screening rates in the severely mentally ill enrolled in California’s Medicaid program and noted lower than average rates in this population.

Trimodality therapy achieved improved locoregional control among a cohort of women with nonmetastatic inflammatory breast cancer.

Results of a new study suggest that breast cancer–related lymphedema is strongly associated with multimodality treatment, including chemotherapy, and not axillary node surgery alone.

The 2013 ASCO/CAP updates to HER2 testing guidelines did not result in changes to the rate of HER2 positivity among breast cancer patients.

The FDA has approved regorafenib (Stivarga) for the second-line treatment of hepatocellular carcinoma (HCC) for patients who have previously received sorafenib.

Women who undergo bilateral mastectomy for the treatment of DCIS may be overtreated, according to the results of a new study.

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

By clicking Accept, you agree to become a member of the UBM Medica Community.